Analysts Set Albireo Pharma Inc (ALBO) Price Target at $57.75

Share on StockTwits

Albireo Pharma Inc (NASDAQ:ALBO) has been given a consensus recommendation of “Buy” by the eight analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $57.75.

A number of equities analysts have commented on the stock. BidaskClub upgraded shares of Albireo Pharma from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. ValuEngine lowered shares of Albireo Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, March 11th. Wedbush reiterated a “buy” rating and issued a $69.00 price objective on shares of Albireo Pharma in a report on Friday, January 25th. Finally, HC Wainwright assumed coverage on shares of Albireo Pharma in a report on Thursday, February 28th. They issued a “buy” rating and a $62.00 price objective on the stock.

Shares of NASDAQ:ALBO traded down $0.51 during midday trading on Thursday, hitting $30.07. 24,048 shares of the company’s stock traded hands, compared to its average volume of 46,945. The firm has a market capitalization of $368.72 million, a price-to-earnings ratio of -7.63 and a beta of 1.70. Albireo Pharma has a twelve month low of $19.10 and a twelve month high of $37.95.

Albireo Pharma (NASDAQ:ALBO) last posted its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by ($0.18). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $1.94 million. Albireo Pharma had a negative net margin of 361.94% and a negative return on equity of 32.42%. Equities research analysts forecast that Albireo Pharma will post -5.74 EPS for the current year.

Hedge funds have recently modified their holdings of the business. Northern Trust Corp increased its holdings in Albireo Pharma by 533.1% in the second quarter. Northern Trust Corp now owns 99,819 shares of the biopharmaceutical company’s stock valued at $3,544,000 after buying an additional 84,053 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Albireo Pharma by 83.3% in the third quarter. Acadian Asset Management LLC now owns 8,513 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 3,868 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Albireo Pharma by 315.3% in the third quarter. Wells Fargo & Company MN now owns 4,676 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 3,550 shares during the last quarter. Prudential Financial Inc. increased its holdings in Albireo Pharma by 9.0% in the third quarter. Prudential Financial Inc. now owns 25,152 shares of the biopharmaceutical company’s stock valued at $829,000 after buying an additional 2,075 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Albireo Pharma by 8.6% in the third quarter. Bank of New York Mellon Corp now owns 35,023 shares of the biopharmaceutical company’s stock valued at $1,154,000 after buying an additional 2,760 shares during the last quarter. Hedge funds and other institutional investors own 66.85% of the company’s stock.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

See Also: How to find the components of the quick ratio

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VeriME Market Cap Tops $374,353.00
VeriME Market Cap Tops $374,353.00
Molina Healthcare, Inc.  Receives Average Rating of “Hold” from Analysts
Molina Healthcare, Inc. Receives Average Rating of “Hold” from Analysts
SPINDLE  Reaches Market Capitalization of $2.12 Million
SPINDLE Reaches Market Capitalization of $2.12 Million
MediBit Trading 32.3% Higher  Over Last 7 Days
MediBit Trading 32.3% Higher Over Last 7 Days
Clovis Oncology  Expected to Announce Earnings of -$1.80 Per Share
Clovis Oncology Expected to Announce Earnings of -$1.80 Per Share
BUDDY Price Down 36.7% Over Last 7 Days
BUDDY Price Down 36.7% Over Last 7 Days


 
© 2006-2019 Zolmax.